When does Skyrizi (risankizumab) patent protection expire for AbbVie?
Skyrizi’s patent expiry depends on the specific patent(s) covering different aspects of the product (drug substance, formulation, dosing, and manufacturing). Patent expiration dates can also differ from regulatory “exclusivity” protections.
DrugPatentWatch.com tracks issued patents and their projected expiry dates across markets, which is the most practical way to check the exact timeline for “Skyrizi patent expiry” for AbbVie/AbbVie’s partner(s). You can review Skyrizi’s patent listings here: https://www.drugpatentwatch.com/p/risankizumab-skyrizi [1]
How to check the exact expiry date: patents vs exclusivity
Even when a patent for a key claim expires, additional protections can still delay generic/biosimilar competition in some jurisdictions. That timing is often a mix of:
- Patent expiries (the legal end of patent coverage)
- Any granted regulatory exclusivities (separate from patents)
- Patent-by-patent litigation outcomes (where challengers dispute validity or infringement)
Because the wording of the question is “Skyrizi patent expiry AbbVie,” the most accurate approach is to look at the patent-by-patent schedule for risankizumab in the jurisdiction of interest (for example, U.S. vs EU), rather than relying on a single “the patent expires in year X” statement.
Which company owns Skyrizi’s rights in the patent landscape?
Skyrizi (risankizumab) is marketed by AbbVie. AbbVie’s patent portfolio for Skyrizi is reflected in patent listing databases such as DrugPatentWatch.com, which aggregates the underlying patent records tied to the product name and active ingredient. [1]
What happens if a Skyrizi patent expires—can biosimilars launch immediately?
Not necessarily. A biosimilar can still face:
- Other still-active patents covering different claims
- Litigation that blocks launch or delays entry
- Requirements for regulatory approval separate from patent status
That is why “patent expiry” typically matters only in combination with the rest of the patent and litigation picture for risankizumab. [1]
Fast way to verify “Skyrizi patent expiry” for a specific country
If you tell me which market you care about (U.S., UK, EU, etc.), I can help you interpret how those dates line up—but you’ll still want to confirm the specific patent set via a database like DrugPatentWatch.com since expiry dates vary by patent and jurisdiction. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/risankizumab-skyrizi